9 Oak Park Drive
294 articles with Insulet Corporation
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that management will present at three upcoming investor conferences:
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Corinne Nevinny has been appointed to the Company’s Board of Directors, effective immediately.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2018 on February 25, 2019 after the close of the financial markets.
Insulet Corporation announced that Wayde McMillan has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2019, succeeding Michael Levitz
Insulet Corporation today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 8, 2019, at 11:30 a.m. (Pacific Time).
Insulet Corporation today announced that management will present at two upcoming investor conferences
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
Insulet Collaborates with Samsung to Deliver Galaxy Smartphone-Controlled Insulin Pump Delivery System
Incorporates Best-In-Class Cyber-Security Protocols and Mobile App Controlled Omnipod
Highlights Include Beyond Type Run Team NYC Marathon Sponsorship, NASDAQ Closing Bell Ceremony and Global Fundraising Events
Insulet Reports Third Quarter 2018 Revenue of $151.1 Million, Up 24% Year-Over-Year, and Gross Margin Over 67%, Up 700 Basis Points
Achieved Both Positive Operating and Net Income for the First Time in Insulet's History
Omnipod System to be Highlighted at the 54th Annual Meeting of the European Association for the Study of Diabetes in Berlin, Germany
Insulet Corporation today announced plans to release its financial results for the third quarter of 2018 on November 1, 2018
Insulet Announces Shacey Petrovic, President and COO, Promoted to CEO, Effective January 1, 2019; Patrick Sullivan Will Retire as Chairman and CEO at the End of 2018
Timothy Scannell Will Become Chairman of the Board
Insulet Corporation today announced that management will present at two upcoming investor conferences in New York City, New York:
Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference
Insulet Corporation announced it will showcase its recently FDA cleared Omnipod DASH™ Insulin Management System (Omnipod DASH System), during the American Association of Diabetes Educators meeting at the Baltimore Convention Center in Baltimore, Maryland on August 17-20, 2018.
Insulet Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points
Full Year 2018 Expected Revenue Growth Revised to 18% to 21%
Insulet Corporation announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®
Insulet Corporation announced plans to release its financial results for the second quarter of 2018 on August 2, 2018 after the close of the financial markets.
Insulet Partners with the International Diabetes Federation Europe to Support Advocacy Activities Across the Continent
Insulet Corporation announced it has entered into a partnership with the European Region of the International Diabetes Federation (IDF Europe) to collaborate on regional advocacy activities.
Tubeless, Waterproof* Insulin Pump and Wireless, Handheld Personal Diabetes Manager Make Switching from Multiple Daily Injections to Pump Therapy Much Easier